<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03983928</url>
  </required_header>
  <id_info>
    <org_study_id>TQB2450-Ib-11</org_study_id>
    <nct_id>NCT03983928</nct_id>
  </id_info>
  <brief_title>Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer</brief_title>
  <official_title>A Phase Ib, Open-label, Single Center, Non-randomized Study for Safety and Efficacy of TQB2450 Combined With Anlotinib in Subjects With Advanced Mutation Positive Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single center, non-randomized, phase Ib trial to evaluate safety and
      efficacy of TQB2450 injection combined with anlotinib in patients with advanced mutation
      positive non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate （ORR）</measure>
    <time_frame>up to approximately 12 months</time_frame>
    <description>Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to approximately 12 months</time_frame>
    <description>PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to approximately 15 months</time_frame>
    <description>OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate（DCR）</measure>
    <time_frame>up to approximately 12 months</time_frame>
    <description>Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR) and Stable Disease (SD).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>TQB2450 Combined with Anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB2450</intervention_name>
    <description>TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.</description>
    <arm_group_label>TQB2450 Combined with Anlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>a multi-target receptor tyrosine kinase inhibitor</description>
    <arm_group_label>TQB2450 Combined with Anlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Understood and signed an informed consent form.

          2. 18 years and older.

          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, life
             expectancy≥ 12 weeks.

          4. Histologically or cytologically confirmed mutation positive non-small cell lung cancer
             according to 8th International Association for the Study of Lung Cancer (IASLC)
             edition.

          5. Has measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST)
             version 1.1.

          6. Adequate organ system function, defined as follows:

               1. absolute neutrophil count (ANC) ≥ 1.5×10^9/L, platelets (PLT) ≥ 100×10^9/L,
                  hemoglobin (Hb)≥ 90g /L;

               2. total bilirubin (TBIL) ≤ 1.5×ULN；alanine transaminase (ALT) and aspartate
                  aminotransferase (AST) ≤ 3.0 × ULN (without liver metastasis) or ≤ 5.0 × ULN
                  (with liver metastasis), Creatinine ≤ 1.5 × ULN and creatinine clearance ≥ 50
                  ml/min;

               3. Urine protein &lt; ++，or urine protein ≥ ++ concomitant with content of 24-hour
                  urinary protein &lt;1.0 g;

               4. international normalized ratio (INR) ≤ 1.5×ULN, activated partial thromboplastin
                  time (APTT) ≤ 1.5×ULN;

               5. left ventricular ejection fraction (LVEF) ≥ 50%;

          7. Male or female subjects should agree to use an adequate method of contraception
             starting with the first dose of study therapy through 6 months after the last dose of
             study (such as intrauterine devices , contraceptives or condoms) ; No pregnant or
             breastfeeding women, and a negative pregnancy test are received within 7 days before
             the randomization.

        Exclusion Criteria:

          1. Has diagnosed and/or treated additional malignancy within 5 years prior to
             randomization except of cured in situ carcinoma of the cervix, non-melanoma skin
             cancer and superficial bladder carcinoma.

          2. Has severe hypersensitivity reactions after taking other monoclonal antibodies.

          3. Has hypersensitivity reactions after taking anlotinib.

          4. Has prior therapy with anlotinib, anti-programmed cell death (PD)-1, anti-PD-L1 or
             other immunotherapy against PD-1/PD-L1.

          5. Has any active autoimmune disease or history of autoimmune disease, such as autoimmune
             hepatitis, interstitial pneumonia, enteritis, vasculitis, nephritis, asthma patients
             who need bronchiectasis for medical intervention; Subjects with the vitiligo without
             systemic treatment, psoriasis, alopecia, well-controlled type I diabetes mellitus,
             hypothyroidism stable on hormone replacement will not be excluded from this study.

          6. Has multiple factors affecting oral medication, such as inability to swallow,
             post-gastrointestinal resection, chronic diarrhea and intestinal obstruction, etc.

          7. Has clinical significance of thyroid dysfunctions within 6 months prior to enrollment,
             and even though medical therapy, thyroid function can not return to normal or no
             clinical significance.

          8. Has central nervous system (CNS) metastases without local therapy of lesion.

          9. Radiograph (within 28 days before enrollment) showed that the tumor surrounded
             important blood vessels, and the investigators determined that entering the study
             would cause bleeding risk.

         10. Hemoptysis (defined as coughing out or spitting out ≥ 1 teaspoon of blood or small
             blood clots or hemoptysis without sputum) within 28 days before enrollment , not
             including bloody sputum.

         11. Immunosuppressive therapy with immunosuppressive agents or systemic or absorbable
             local hormones (dosage &gt; 10 mg/day prednisone or other therapeutic hormones) is
             required for the purpose of immunosuppression, and is still in use for 2 weeks after
             the first administration.

         12. Has any of the following severe acute complications:

               1. Unstable angina and/or congestive heart failure or vascular disease requiring
                  hospitalization within 12 months, or other cardiac impairments determined by the
                  investigator, which may affect the evaluation of drug safety; Myocardial
                  infarction or ischemia with ST elevation ≥ 2 mm indicated by electrocardiogram
                  (ECG);

               2. Has pulmonary infections and/or acute bacterial or fungal infections requiring
                  intravenous antibiotic therapy;

               3. Has clinical jaundice caused by liver dysfunction;

         13. Virological test indicates one of the following items before enrollment:

               1. HBsAg positive and HBV DNA ≥ 1 × 10^3 copies/mL;

               2. Anti-HCV positive and HCV virus titer detection value exceeds the upper limit of
                  normal value;

               3. HIV positive;

         14. Has participation in an anti-tumor clinical trial within 28 days prior to the first
             administration.

         15. Has serious affecting safety or treatment compliance concomitant diseases, according
             to the investigator's judgment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Li Zhang</last_name>
    <phone>020-87343458</phone>
    <email>zhangli@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zhang</last_name>
      <phone>020-87343458</phone>
      <email>zhangli@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 10, 2019</study_first_submitted>
  <study_first_submitted_qc>June 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2019</study_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

